Seeking Alpha

FBR sees huge upside for Novavax on RSV vaccine potential

  • Novavax (NVAX +8.3%) is up sharply in morning trading.
  • Helping the cause is FBR's William Tanner, who calls the company "one of the mos compelling small-cap vaccine plays in the biopharma sector by virtue of the vaccine for preventing RSV infection."
  • Although Tanner thinks absence of visibility into stockpiling plans makes it "difficult to ascribe much value" to NVAX's pandemic vaccine programs, he says that "if safe and effective, the [RSV] vaccine could have broad utility for preventing infection in pregnant women, neonates (by virtue of maternal vaccination), infants, and young children and the elderly."
  • Shares initiated at Outperform.
  • Price target is $11, representing upside of around 280% from Tuesday's close.
Comments (3)
  • Shane Blackmon
    , contributor
    Comments (502) | Send Message
     
    On Aug 15th, same analyst initiated with same PT of $11/share... moved from Lazard to FBR... it's kind of old news.

     

    Good luck to all.
    30 Oct 2013, 11:18 AM Reply Like
  • theTalkativeOne
    , contributor
    Comments (51) | Send Message
     
    Thanks but Lazard was one and FBR makes two. That's 100% increase not to mentioned since Lazards call the stocks held firm. Old news?
    30 Oct 2013, 12:36 PM Reply Like
  • Shane Blackmon
    , contributor
    Comments (502) | Send Message
     
    I'm not sure you are understanding what i am saying...
    Everyone jumped ship from Lazard, the analyst at Lazard is the current analyst at FBR. It's the same person, making the same call at a different firm.

     

    He initiated on over a dozen names today, the same names he covered at Lazard.
    30 Oct 2013, 02:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector